DSIP
Aliases: Delta Sleep-Inducing Peptide
Last verified: 2026-09-23
The short version
A nonapeptide discovered in 1977 in rabbit brain during sleep; named for inducing delta (deep) sleep. Used for sleep quality, stress and chronic pain. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Numerous older European studies (insomnia, addiction, pain) with mixed results; no modern clinical development. Status: research chemical. Not approved; research chemical.
Identity & type
- Molecular type
- peptide
- Origin
- A nonapeptide discovered in 1977 in rabbit brain during sleep; named for inducing delta (deep) sleep.
Mechanism of action
Modulates GABA/glutamate and NMDA systems, normalizes cortisol and LH, antistress action; exact receptor unidentified.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for DSIP. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
100–250 mcg SC in the evening 1–2 h before bed. Polarizing effects: some report deep, restorative sleep and easy waking, others nothing; a subset experiences next-day sleepiness.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Polarizing effects: some report deep, restorative sleep and easy waking, others nothing; a subset experiences next-day sleepiness.
Protocol — official vs community
Official / label
No approved product. Research intranasal/IV use; human sleep studies are small and old.
Duration: Study use only.
Delta-sleep-inducing peptide — the name wrote a cheque the trials never cashed.
Community (anecdotal)
100–200 mcg SC or 50–100 mcg intranasal before bed.
- Cycle:
- Continuous nightly or 4–8 week courses.
- Break:
- None standardized.
Anecdotal reports split: some find it profound, most find it inert — the classic signature of a weak effect plus strong expectancy.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Numerous older European studies (insomnia, addiction, pain) with mixed results; no modern clinical development.
Preclinical evidence
Numerous older European studies (insomnia, addiction, pain) with mixed results; no modern clinical development.
Known risks
- Rare: headache, dizziness; paradoxical stimulation in some.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.